Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1 1

Status

Completed 4Recruiting 2Not yet recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 2Weight Loss 1Pediatric Obesity 1Obesity 1Neoplasms 1Multiple Myeloma 1Gynecologic Cancers 1Emotional Regulation 1Anemia 1

Interventions

Fulvestrant 58Trastuzumab 49Capecitabine 48Letrozole 45pembrolizumab 41Carboplatin 41Paclitaxel 39Cyclophosphamide 38ribociclib 37pertuzumab 36abemaciclib 36Blood Specimen Collection 31Specimen Handling 28trastuzumab deruxtecan 27Docetaxel 27Surveys and Questionnaires 26Anastrozole 25exemestane 24Tamoxifen 24palbociclib 21130-nm albumin-bound paclitaxel 21Magnetic Resonance Spectroscopy 20Biopsy 19sacituzumab govitecan 18eribulin 18Radiotherapy 18Gemcitabine 18olaparib 17Injections 17Epirubicin 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Breast Neoplasms × Population Groups × Clear all
NCT05984888 2025-10-03

MIND-BC

Ohio State University Comprehensive Cancer Center

Phase NA Recruiting
43 enrolled
Breast

Breast Neoplasms

NCT06770296 2025-01-13

The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase I Clinical Study

The First Affiliated Hospital with Nanjing Medical University

Phase 1 Recruiting
200 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡